Dear Fellow Shareholders of Nutra Pharma: As 2009 comes to a close, I wanted to write this letter to express my gratitude for your continued support and to take a moment to reflect on our progress over the past year. 2009 was a pivotal year for Nutra Pharma. While other companies around the world suffered [...]

Read Full Post »

Several months ago we decided to let go of 18 patents that we had originally licensed from NanoLogix for use with our Designer Diagnostics test kit technology. We were no longer using these patents and they are not material to Nutra Pharma, so it did not make sense for us to continue paying hefty royalties [...]

Read Full Post »

On Friday, an article came out from Dow Jones Newswires that discussed Nutra Pharma and our launch of Cobroxin. While the article was factually correct and well written, the author left out critical pieces of information that failed to tell the entire story about Nutra Pharma. While at first glance, our balance sheet looks soft. [...]

Read Full Post »

Just over 2 weeks ago, we announced the launch of Cobroxin, a pain reliever developed by our subsidiary, ReceptoPharm.  Since making that announcement, we have been inundated with calls and emails asking us about Cobroxin and our launch strategy. To help answer these questions, I have put together the following list of some of the [...]

Read Full Post »

Over 50 million Americans suffer from ongoing chronic pain, but that’s all about to change. In August, a biotechnology company, Nutra Pharma, shook the pain world when it announced the launch of Cobroxin, a safe and effective over-the-counter treatment for chronic pain. Unlike many popular pain medicines, Cobroxin does not rely on opiates or acetaminophen [...]

Read Full Post »